TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22031171

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 or 20 mg/day depending on weight)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 19539430

Group type: EXPERIMENTAL
Intervention: Platinum chemotherapy regimens
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Taxane chemotherapy regimens
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Combination of platinum and taxane chemotherapy regimens
Number of subjects: 683

Group type: COMPARATOR
Intervention: Monotherapy with an agent other than platinum or taxane
Number of subjects: 683
Study: 17855199

Group type: EXPERIMENTAL
Intervention: Endoscopic radial artery harvesting (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional radial artery harvesting (group B)
Number of subjects: 50
Study: 14678347

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (1200 microg)
Number of subjects: 16
Study: 12231083

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril 6.25 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg once daily (2-week treatment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Captopril 12.5 mg twice daily (2-week treatment)
Number of subjects: 24
Study: 9844955

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug-free condition
Number of subjects: 0
Study: 8008342

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) injections (5 mg, five injections over 2 weeks post-surgery)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) injections
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no injections)
Number of subjects: 62
Study: 2937740

Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFX) for 10 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPX) for 10 days
Number of subjects: 20
Study: 30261617

Group type: EXPERIMENTAL
Intervention: High-Oleic Acid meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-Linoleic Acid meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-Carbohydrate Control meal
Number of subjects: 8
Study: 27797248

Group type: EXPERIMENTAL
Intervention: Surgical resection 6-8 weeks after neoadjuvant CRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical resection 9-14 weeks after neoadjuvant CRT
Number of subjects: 0
Study: 24549160

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide (18 μg) once daily inhaled capsule
Number of subjects: 839

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 839
Study: 21986341

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention comprising 12 individual weekly sessions
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 201
Study: 20301228

Group type: EXPERIMENTAL
Intervention: Patient-led teaching
Number of subjects: 42

Group type: COMPARATOR
Intervention: Doctor-led teaching
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Knowledge test
Number of subjects: 42
Study: 18574929

Group type: EXPERIMENTAL
Intervention: Therapy for early stage patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antiparkinsonian therapy for late stage patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 60
Study: 19127915

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhongwan (CV 12), Tianshu (ST 25), Guanyuan (CV 4) combined with diet control
Number of subjects: 334

Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 334

Group type: COMPARATOR
Intervention: Diet control
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Observation group and control group I
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group II
Number of subjects: 334
Study: 15160570

Group type: EXPERIMENTAL
Intervention: Topical placental extract
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study: 11219875

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional analgesic management
Number of subjects: 0
Study: 9341696

Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurement of carotid artery IMT
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Ultrasound-detected carotid atherosclerosis
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Associations with IMT
Number of subjects: 202
Study: 8476402

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment
Number of subjects: 67

Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 67
Study: 2878389

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30736918

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photo-enhanced Imaginative (PIC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral condition (no contextual exposure)
Number of subjects: 60
Study: 29952641

Group type: EXPERIMENTAL
Intervention: Midazolam (0.04 mg/kg) with propofol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 56
Study: 27289438

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) electrolyte testing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Traditional serum chemistry testing
Number of subjects: 225
Study: 24937017

Group type: EXPERIMENTAL
Intervention: Automated, data-driven, electronic health record-embedded program to identify patients due for colorectal screening and mail FIT kits with pictographic instructions; improvement process (Plan-Do-Study-Act) to enhance adoption and effectiveness.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Opportunistic colorectal-cancer screening provided at clinic visits.
Number of subjects: 26
Study: 21163585

Group type: EXPERIMENTAL
Intervention: Low-level laser (LLL) therapy 2.5 J/cm(2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 75
Study: 19223151

Group type: EXPERIMENTAL
Intervention: 10.8mg yohimbine hydrochloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17698433

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture for 8 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sham acupuncture (non-smoking-cessation-related acupoints) for 8 weeks
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 118
Study: 15356829

Group type: EXPERIMENTAL
Intervention: Amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amprenavir-ritonavir (APV-RTV) 1200/200 mg q.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both regimens (APV-RTV 600/100 mg b.i.d. and APV-RTV 1200/200 mg q.d.)
Number of subjects: 0
Study: 11855793

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both enalapril and losartan
Number of subjects: 34
Study: 9926292

Group type: EXPERIMENTAL
Intervention: Vitamin C 5g daily for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antacids for 4 weeks (Control)
Number of subjects: 60
Study: 7529856

Group type: EXPERIMENTAL
Intervention: Post-operative Gleason score
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: HER-2/neu antigenicity
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: CAS-200 DNA ploidy
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Twelve Markovian nuclear texture and shape features
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PCNA
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Best Markovian features combined with post-operative Gleason score
Number of subjects: 124
Study: 2831525

Group type: EXPERIMENTAL
Intervention: 20 mg of enalapril
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 50 mg of atenolol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 40 mg of enalapril (after dosage increase)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol (after dosage increase)
Number of subjects: 58
Study: 31990730

Group type: EXPERIMENTAL
Intervention: Gum chewing for 2 minutes before induction of anesthesia (group G)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (group C) asked to swallow twice without additional treatment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Gum chewing (group G)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Gum chewing (group G) in patients with bloody SGA devices
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (group C) in patients with bloody SGA devices
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Gum chewing (group G) in patients without bloody SGA devices
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (group C) in patients without bloody SGA devices
Number of subjects: 140
Study: 29358539

Group type: EXPERIMENTAL
Intervention: 625 mg of combined amoxicillin and clavulanic acid tablet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 625 mg of combined amoxicillin and clavulanic acid tablet + 400 mg metronidazole tablet
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study: 27241670

Group type: EXPERIMENTAL
Intervention: Manual aspiration (group 1)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Wall suction (group 2)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study: 25596929

Group type: EXPERIMENTAL
Intervention: Intervention program for children exposed to IPV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waitlist comparison condition
Number of subjects: 120
Study: 22984173

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 20837926

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18412944

Group type: EXPERIMENTAL
Intervention: Real rTMS treatment (1 Hz for 2 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 150
Study: 16485876

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with topical 5‐aminolevulinic acid (ALA), treated 4 times weekly with 30‐minute ALA incubation and blue light activation.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Topical clindamycin, used as control treatment.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Patient satisfaction for ALA PDT-treated side.
Number of subjects: 21
Study: 11979068

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10426835

Group type: EXPERIMENTAL
Intervention: Ambulatory intermittent dobutamine infusion at 2.5 microgram/kg/min for 48 hours/week for 6 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Optimal standard treatment (control group)
Number of subjects: 38
Study: 7560119

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.1 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 2376246

Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV) 6 h per day for 5 consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 10
Study: 7372783

Group type: EXPERIMENTAL
Intervention: Intravenous beta-endorphin infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 10
Study: 31739173

Group type: EXPERIMENTAL
Intervention: Vitamin D status (s-25(OH)D3)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-overweight status
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-sun vacations
Number of subjects: 212
Study: 30554861

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 27930452

Group type: EXPERIMENTAL
Intervention: Multiple CHO + protein (MCP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multiple CHO (MCO)
Number of subjects: 10
Study: 26353829

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (1,600 IU/day for <1 year old, 2,400 IU/day for >1 year old)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual intake of vitamin D (400 IU for <1 year old, 600 IU for >1 year old)
Number of subjects: 62
Study: 23368915

Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) supplemented parenteral nutrition (PN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous parenteral nutrition (PN) without ω‐3 PUFAs
Number of subjects: 60
Study: 21269649

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with implantation of the CorCap cardiac support device (treatment group)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control group)
Number of subjects: 193
Study: 19149978

Group type: COMPARATOR
Intervention: Ivermectin (150 microg/kg orally)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day for 6 weeks) followed by Ivermectin (150 microg/kg orally)
Number of subjects: 240
Study: 17640544

Group type: EXPERIMENTAL
Intervention: Timely revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump counterpulsation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ventricular assist devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergent heart transplantation
Number of subjects: 0
Study: 15154636

Group type: EXPERIMENTAL
Intervention: Allopurinol ice balls
Number of subjects: 32

Group type: COMPARATOR
Intervention: No allopurinol ice balls
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Allopurinol ice balls after initial stomatitis
Number of subjects: 32
Study: 11208636

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg twice daily
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 9033439

Group type: EXPERIMENTAL
Intervention: Salmeterol 21 micrograms twice daily
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Salmeterol 42 micrograms twice daily
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 8331545

Group type: EXPERIMENTAL
Intervention: 60 mg of APD over 4 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: 60 mg of APD over 24 h
Number of subjects: 20
Study: 3579263

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 41

Group type: COMPARATOR
Intervention: Ampicillin-Chloramphenicol
Number of subjects: 41
Study: 31278458

Group type: EXPERIMENTAL
Intervention: Phenolisation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radical excision
Number of subjects: 100
Study: 28630396

Group type: EXPERIMENTAL
Intervention: Pulse lavage (PL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Closed drainage (CD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iodine lavage (IL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline lavage (SL)
Number of subjects: 0
Study: 24053189

Group type: EXPERIMENTAL
Intervention: New alternating pressure air mattress (APAM) with low friction layer and novel air-cell pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control alternating pressure air mattress (APAM)
Number of subjects: 0
Study: 23183351

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.02% for 5 seconds
Number of subjects: 184

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 184
Study: 20932155

Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (SDD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19772521

Group type: EXPERIMENTAL
Intervention: Gene-targeted mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RANKL
Number of subjects: 0
Study: 16237386

Group type: EXPERIMENTAL
Intervention: estradiol (Estrofem; 2 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: buspirone (Buspar; 5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: combined buspirone and estradiol
Number of subjects: 11
Study: 15504379

Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg mifepristone and 1 mg gemeprost)
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Surgical abortion (vacuum aspiration in general anesthesia)
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1135
Study: 10843450

Group type: EXPERIMENTAL
Intervention: Prazosin 0.5 mg twice daily
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Terazosin 0.5 mg twice daily
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.1 mg once daily
Number of subjects: 121
Study: 9112292

Group type: EXPERIMENTAL
Intervention: 3 MIU x 3 per week for 6 months (arm A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 6 MIU x 3 per week for 3 months and then 3 MIU x 3 per week for 3 months (arm B)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Genotype 1a
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Genotype 1b
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Genotype 2
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Genotype 3
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sustained HCV RNA response
Number of subjects: 116
Study: 8226457

Group type: EXPERIMENTAL
Intervention: H10/1 protocol (10 repetitions maximum with 1-min rest)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: S10/3 protocol (strength protocol with 10 repetitions maximum and 3-min rest)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H10/1 protocol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H5/1 protocol (5 repetitions maximum with 1-min rest)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: H10/1 and H5/1 protocols
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All three protocols in series 1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HREPs (heavy-resistance exercise protocols)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: HREPs
Number of subjects: 9
Study: 3100464

Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E1 (PGE1) analogue
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2839813

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine MMU 18006 (10^5, 10^4, or 10^3 plaque-forming units)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine MMU 18006
Number of subjects: 34
Study: 29948666

Group type: COMPARATOR
Intervention: Conventional fluid management (CFM)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PVI-guided goal‐directed fluid management (GDFM)
Number of subjects: 70
Study: 28629338

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (intermittent exercise, combining moderate and high intensities; 55 minutes duration, 3 times per week)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard oncological care
Number of subjects: 112
Study: 26121986

Group type: EXPERIMENTAL
Intervention: Client-centred ADL intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual ADL intervention
Number of subjects: 280
Study: 23763469

Group type: EXPERIMENTAL
Intervention: Experimental vignette
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control vignette
Number of subjects: 90
Study: 21570291

Group type: EXPERIMENTAL
Intervention: Neutral patella taping
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patellofemoral bracing
Number of subjects: 13

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 13
Study: 19483109

Group type: EXPERIMENTAL
Intervention: Th2-high asthma
Number of subjects: 42

Group type: COMPARATOR
Intervention: Th2-low asthma
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 42
Study: 16908478

Group type: EXPERIMENTAL
Intervention: Social Responsiveness Scale (SRS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Composite
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Autism Diagnostic Interview‐Revised
Number of subjects: 73
Study: 14558397

Group type: EXPERIMENTAL
Intervention: Topical 20% 5-aminolevulinic acid (5-ALA) followed by 595 nm pulsed dye laser (PDL) irradiation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) treatment alone or untreated lesions
Number of subjects: 10
Study: 10674589

Group type: EXPERIMENTAL
Intervention: Rollerball endometrial ablation
Number of subjects: 39
Study: 9060894

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 8403573

Group type: EXPERIMENTAL
Intervention: 5 U/kg (G5)
Number of subjects: 107
Study: 3804884

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenously every 12 h for mean duration 8.7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefamandole (1.5 g intravenously every 6 h for mean duration 8.2 days)
Number of subjects: 30
Study: 30839013

Group type: EXPERIMENTAL
Intervention: Fish oil (FO, n = 35, 2 g day‐1 eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FLO, n = 39, 2.5 g day‐1 α‐linolenic acid)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FLO)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Corn oil (CO, n = 34)
Number of subjects: 108
Study: 28335886

Group type: EXPERIMENTAL
Intervention: OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy)
Number of subjects: 85

Group type: COMPARATOR
Intervention: CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29)
Number of subjects: 85